Danaher Corp. agreed to acquire Masimo Corp. for $9.9 billion, buying all outstanding shares at $180 each in cash. Danaher said the acquisition strengthens its diagnostics franchise and expands point‑of‑care and monitoring capabilities. The deal values Masimo at a roughly 38% premium to its last close and follows strategic consolidation trends in med‑tech where larger industrial diagnostics players are consolidating monitoring, sensing and diagnostic platforms. Danaher will integrate Masimo’s pulse oximetry and noninvasive monitoring technologies into its broader life‑sciences and diagnostics portfolio. Regulatory review and integration execution will determine near‑term synergies and any divestiture requirements; shareholders and customers will watch product roadmaps and service continuity closely during the transition.